Do you want to read an article? Please log in or register.
Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction
Heart Failure
Related content
Heart Failure
Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
JAMA.
Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, McCague K, Abbas CA, Rocha R, Mitchell GF, EVALUATE-HF Investigators.
doi: 10.1001/jama.2019.12843.
Heart Failure
Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial
Eur J Heart Fail.
Bouabdallaoui N, Claggett B, Zile MR, McMurray JJV, O'Meara E, Packer M, Prescott MF, Swedberg K, Solomon SD, Rouleau JL; PARADIGM-HF Investigators and Committees
doi: 10.1002/ejhf.1301.
Atrial FibrillationHeart FailureHypertension
Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry
Eur J Heart Fail.
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G
doi: 10.1002/ejhf.813.
Heart Failure
Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF)
JACC Heart Fail.
Luo N, Fonarow GC, Lippmann SJ, Mi X, Heidenreich PA, Yancy CW, Greiner MA, Hammill BG, Hardy NC, Turner SJ, Laskey WK, Curtis LH, Hernandez AF, Mentz RJ, O'Brien EC
doi: 10.1016/j.jchf.2016.12.018.
RECOMMENDED
Heart Failure
Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Circulation.
McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer NK, Vardeny O, Claggett B, Jhund PS, Solomon SD
doi: 10.1161/CIRCULATIONAHA.119.044491.
Heart Failure
Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction
JACC Heart Fail.
Tan NY, Sangaralingham LR, Sangaralingham SJ, Yao X, Shah ND, Dunlay SM
doi: 10.1016/j.jchf.2019.08.003.
Heart Failure
Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study
Eur J Heart Fail.
Nougué H, Pezel T, Picard F, Sadoune M, Arrigo M, Beauvais F, Launay JM, Cohen-Solal A, Vodovar N, Logeart D
doi: 10.1002/ejhf.1342.
Heart Failure
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Eur Heart J
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Rocca HB, Janssens S, Tsutsui H, Zhang J, Brueckmann M, Jamal W, Cotton D, Iwata T, Schnee J, Zannad F
doi: 10.1093/eurheartj/ehaa968
Heart, Artery and Coronary DiseasesHeart Failure
Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)
Eur J Heart Fail.
Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goetschalckx K, Pfister O, Pfisterer M, Brunner-La Rocca HP; TIME-CHF Investigators
doi: 10.1002/ejhf.798.